瑞士制药巨头罗氏与中国生物科技公司朗诺医药于本周二宣布，双方已就一款处于研发阶段的减肥药达成许可协议，交易总额最高可达11.6亿美元。
Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics ZURICH, Oct 13 - Swiss drugmaker Roche entered a licensing agreement worth up to $1.16 billion with Rona Therapeutics for its investigational obesity drug candidate, the Chinese biotech firm said on Tuesday.
此次合作有助于罗氏进一步进军目前由礼来与诺和诺德主导的减肥药市场。根据协议，朗诺医药将获得1亿美元的首付款，并有望获得最高10.6亿美元的里程碑付款，此外还能从该药物的全球净销售额中获得分级特许权使用费。
Roche has been racing to break into the obesity drug market dominated by Eli Lilly and Novo Nordisk. • With the deal, Rona Therapeutics is set to receive an upfront payment of $100 million and is eligible to receive up to $1.06 billion in potential milestone payments, as well as tiered royalties on global net sales.
该研发中的RNA干扰疗法以激活素受体样激酶7为作用靶点，这一靶点与肥胖症及各类代谢性疾病密切相关。值得一提的是，今年9月罗氏曾公布其另一款针对肥胖与糖尿病的候选药物enicepatide在中期临床试验中表现优异，该药物能有效帮助患者减轻体重并降低血糖水平。
• The investigational RNAi candidate targets activin receptor-like kinase 7 (ALK7), a target for obesity and metabolic diseases. • In September, Roche reported positive mid-stage data for its obesity and diabetes candidate enicepatide, which helped patients lose weight and lower blood sugar levels.